Levothyroxine Recall: What Patients Need to Know

Rubric: Health
Format: Special Report
Author: Sinisa Brkic (sb)

Certain lots of levothyroxine sodium tablets distributed under the Major Pharmaceuticals and Cardinal Health labels are being recalled nationwide because they may contain less active medication than stated. The recall does not affect every levothyroxine product, and the confirmed problem is reduced potency, not contamination. Patients should check their medication with a pharmacist but should not stop treatment or change their dose without medical guidance.

A specific recall, not a nationwide withdrawal of every product

The recall involves selected lots of levothyroxine sodium tablets, a medication used to replace the thyroid hormone T4 in people whose bodies do not produce enough of it. Major Pharmaceuticals initiated the voluntary recall on July 13, 2026, after stability testing indicated that certain tablets might not meet the required potency specification.

The FDA subsequently classified the action as a Class II recall. This classification means that exposure to the affected medication may cause temporary or medically reversible health consequences, while the probability of serious permanent harm is considered remote.

That distinction is important. The recall does not apply to every levothyroxine prescription, every dosage strength or every manufacturer operating in the United States. Patients must identify the specific manufacturer, distributor, strength, National Drug Code, lot number and expiration date associated with their medication. The tablets were distributed nationwide in unit dose blister packaging under the Major Pharmaceuticals and Cardinal Health labels. Patients who receive tablets in pharmacy containers rather than the original packaging may not be able to identify the manufacturer or lot without assistance from the dispensing pharmacy.

What went wrong with the recalled tablets

The confirmed quality problem is subpotency. This means that the tablets may contain less levothyroxine than the amount stated on the label, potentially resulting in a patient receiving an insufficient dose over time.

There is no confirmed evidence that the recalled tablets are contaminated, poisoned or mixed with an undisclosed substance. Describing the medication as toxic would misrepresent the reason for the recall and could encourage patients to make unsafe treatment decisions.

Levothyroxine dosing is often adjusted carefully according to laboratory results, symptoms, age, medical history and the reason for treatment. Even relatively small changes in the amount absorbed by the body can matter for patients whose hormone levels need to remain within a narrow therapeutic range.

The potential effect also depends on how long a patient has taken tablets from an affected lot and how far below the required potency the tablets may be. Public recall information has not established that every tablet in every listed package contains the same degree of reduced potency.

Strengths and lots identified in recall listings

Published recall information identifies seven levothyroxine strengths and several production lots. Patients should not rely on tablet color or dosage strength alone because most tablets in these strengths are not part of the recall.

Related ten tablet blister packages carrying versions of the listed lot numbers that end in the letter A or B may also be included. Because repackaging and pharmacy labeling can make product identification difficult, the dispensing pharmacy remains the most reliable point of verification.

Patients should provide the pharmacy with the prescription number, medication strength, dispensing date and any manufacturer or lot information visible on the package. The pharmacy can compare its dispensing records with the recall notice and determine whether a replacement is necessary.

The presence of one of the affected dosage strengths does not by itself mean that a prescription has been recalled. A 50 microgram tablet from another manufacturer or another Major Pharmaceuticals production lot is not automatically included.

Why reduced potency can become medically significant

Levothyroxine replaces or supplements a hormone that regulates metabolism, body temperature, heart function, digestion, muscle activity and neurological development. When the dose is too low for a sustained period, signs of insufficient thyroid hormone treatment may gradually return.

Possible symptoms can include fatigue, increased sensitivity to cold, constipation, difficulty concentrating, dry skin, muscle weakness, slowed thinking and unexplained weight gain. Some patients may notice few immediate changes, particularly when the reduction in potency is limited or exposure has been brief.

Symptoms alone cannot confirm that a recalled tablet has caused inadequate treatment. Many of the same complaints can result from other medical conditions, and thyroid status is generally assessed through clinical evaluation and laboratory testing.

Patients who suspect that their treatment has become less effective should contact their physician rather than increasing the dose themselves. Taking additional tablets without medical direction could later produce excessive hormone exposure after the patient receives a correctly formulated replacement.

Some patients require closer attention

The medical significance of reduced potency is not identical for every patient. People who depend entirely on replacement hormone after thyroid removal or radioactive iodine treatment may have less physiological capacity to compensate for an inadequate dose.

Pregnant patients also require particular care because thyroid hormone supports maternal health and fetal development. A pregnant patient who believes she may have received tablets from an affected lot should promptly contact both the prescribing clinician and the pharmacy.

Infants and children receiving levothyroxine require precisely managed treatment because thyroid hormone is important for growth and neurological development. Parents and caregivers should not interrupt pediatric treatment while waiting for confirmation from a pharmacy or clinician.

Older adults and patients with significant heart disease may also require careful supervision when treatment is changed. Rapid or unsupervised dose adjustments can create risks of their own, particularly when cardiovascular conditions are present.

Patients receiving levothyroxine as part of thyroid cancer management may have individualized thyroid stimulating hormone targets. These patients should follow the instructions of their endocrinologist or oncology team rather than relying on general consumer advice.

Do not stop taking levothyroxine without guidance

Patients should not abruptly discontinue levothyroxine solely because their dosage strength appears on a recall list. The FDA’s general guidance for Class II recalls states that patients can usually continue taking the medication unless the recalling company or the agency provides different instructions.

Stopping treatment completely may expose a patient to a greater loss of thyroid hormone than continuing a potentially modestly underpotent dose for a limited period. The safest response is to verify the product quickly and arrange a replacement through the pharmacy when the prescription is confirmed as affected.

Patients should also avoid doubling a dose, combining tablets or switching between products without instructions. Levothyroxine products contain the same active hormone, but changes in formulation, absorption and administration can influence thyroid laboratory values in some patients.

A pharmacist can determine whether an unaffected supply is available and explain how the recalled medication should be returned. The prescribing physician can decide whether a replacement prescription, dose review or laboratory assessment is appropriate.

How patients should check their medication

The first step is to examine the original package, blister card or pharmacy label. Patients should look for the medication name, dosage strength, manufacturer or distributor, NDC, lot number and expiration date.

Those who received loose tablets in a standard prescription bottle should call the dispensing pharmacy. The pharmacy’s records should identify the product source and the lot used when the prescription was filled, even when that information does not appear on the patient label.

Patients should ask the pharmacy four direct questions: whether the dispensed product came from Major Pharmaceuticals or Cardinal Health, whether the lot is included in the recall, whether a replacement is available and how the recalled medication should be returned.

Medication should not be discarded before the pharmacy confirms the correct return or replacement procedure. Keeping the package and prescription information available can help the pharmacy document the affected product and process an exchange.

When laboratory testing may be considered

A recalled prescription does not automatically mean that every patient requires immediate blood testing. The need for testing depends on the affected lot, the duration of exposure, the patient’s clinical condition, the treatment target and the judgment of the treating clinician.

Physicians commonly evaluate thyroid treatment using thyroid stimulating hormone, often together with free T4. Changes in these values may take time to become fully apparent, which is why the timing of any laboratory test should be determined by a medical professional.

Testing may receive greater consideration when a patient has used the affected product for an extended period, develops symptoms or belongs to a medically vulnerable group. Pregnant patients, young children, patients without a functioning thyroid and people receiving thyroid cancer related hormone suppression may require more individualized assessment.

Patients should not assume that a normal result from an earlier test rules out a later effect. The relevant question is whether the test reflects the period during which the affected tablets were taken.

What a Class II recall actually means

A Class II designation is neither the FDA’s highest risk classification nor a statement that the product is harmless. It reflects the agency’s assessment that the defect could cause temporary or medically reversible consequences, while serious adverse health outcomes are considered unlikely.

The classification also helps explain why the recall may have appeared in the FDA’s enforcement reporting system before many patients encountered broad public warnings. Not every drug recall receives an immediate standalone consumer announcement, particularly when the agency considers the risk manageable through retail and pharmacy level action.

This process can create a communication gap. A recall may be active within the supply chain while many patients remain unaware until pharmacies, professional organizations or news outlets circulate the details more widely.

The delayed surge in public attention does not establish that the recall expanded in early August. As of August 6, no newly confirmed nationwide expansion beyond the publicly identified products and lots had been established.

Important questions remain unanswered

The available recall information does not yet provide a complete public accounting of how many blister packages reached patients or how many remained in pharmacy inventories when the recall began. A comprehensive list of every pharmacy, health system and distributor that received the affected lots has also not been publicly established.

It remains unclear how far below the labeled potency the tested tablets fell and whether the reduction was consistent across all affected lots. The precise manufacturing or stability failure that caused the tablets to fall outside specification has not been fully explained in public recall material.

No definitive public total of adverse events, abnormal laboratory findings or treatment failures linked specifically to these lots has been established. Reports of symptoms would also require clinical assessment before a causal connection could be made.

Patients should therefore distinguish between a confirmed product defect and unverified claims about individual harm. The recall confirms a potency problem in selected lots, but it does not prove that every person who received one of those lots suffered a medical consequence.

Precision matters more than panic

Levothyroxine is essential treatment for millions of Americans, and a potency failure deserves prompt attention. It does not justify a blanket warning against the medication itself or an assumption that every prescription is unsafe.

The appropriate response is specific and practical. Patients should check the product details, contact the dispensing pharmacy, speak with the prescribing clinician when necessary and continue treatment unless instructed otherwise by a qualified professional.

This recall is also a test of how effectively drug safety information reaches people who may never see an FDA enforcement report. The medication supply chain can identify and remove defective lots, but that system only protects patients fully when the warning is communicated with enough precision to support action without provoking unnecessary fear.

This report provides general safety information and does not replace individual medical advice. Anyone experiencing significant symptoms or a sudden deterioration in health should seek appropriate medical care.